Shuttle first patient enrollment, dosing in Phase 2 Ropidoxuridine line

Shuttle Pharmaceuticals (SHPH) announced first patient enrollment and dosing at the UVA Cancer Center in its Phase 2 Clinical Trial of Ropidoxuridine for the treatment of patients with glioblastoma. UVA is one of six cancer centers conducting the clinical trials. Shuttle Pharma previously announced the dosing of patients at Miami Cancer Institute, part of Baptist Health South Florida.The Phase 2 trial will consist initially of 40 patients randomized into two different doses